UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8
UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.
Stocks · News reference
BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — BioAge Labs, Inc. (BIOA)
Filed: 2026-10-02 AccNo: 0001193125-26-412300 Size: 169 KB Item 8.01: Other Events
Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target